Company profile: Canopy Biosciences
1.1 - Company Overview
Company description
- Provider of biotechnological products and services for gene editing and personalized medicine, including TUNR technology targeting translation elongation by inserting polyA tracks to decrease mRNA levels. Offerings include CellScape for spatial biology and multi-omic imaging with biomarker quantification; ChipCytometry for quantitative protein biomarker measurement; NanoString nCounter gene expression analysis; single-cell transcriptome profiling; and clinical deep phenotyping.
Products and services
- ChipCytometry: Software-integrated platform combining high-quality imaging with advanced analysis tools to deliver quantitative measurement of protein biomarkers directly in diverse biological samples
- NanoString nCounter Services: Multiplex service quantifying up to 800 genes in a single sample using NanoString nCounter technology
- CellScape: Research-grade benchtop imaging system for spatial biology and multi-omic analysis that enables precise spatial multiplexing and robust quantification of tissue and cell biomarkers
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Canopy Biosciences
Project Farma
HQ: United States
Website
- Description: Provider of healthcare consulting services to pharmaceutical and medical device manufacturers across the supply chain, including GMP-compliant cell and gene therapy facility builds using modular, bioreactor and single-use technologies; business and manufacturing strategy; turnkey capital projects and project management; validation for GMP/GLP/GCP; quality, regulatory and compliance for ISO/GMP; and engineering and automation solutions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Project Farma company profile →
Alliance Pharma
HQ: United Kingdom
Website
- Description: Provider of healthcare solutions through the acquisition and licensing of mature pharmaceutical products, with manufacturing, storage, logistics, and sales operations controlled by Alliance and outsourced to leading specialist organisations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Alliance Pharma company profile →
Irisys
HQ: United States
Website
- Description: Provider of contract pharmaceutical product development and manufacturing services, offering pharmaceutical research and development and formulation development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Irisys company profile →
Explora BioLabs
HQ: United States
Website
- Description: Provider of preclinical, AAALAC-accredited vivarium rental facilities and contract vivarium operation services, delivering turnkey in vivo facilities, management, and related services for biopharmaceutical clients in biotech-dense areas, with vivarium management ensuring maintenance and compliance and CRO options to support early-stage research.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Explora BioLabs company profile →
Medivir
HQ: Sweden
Website
- Description: Provider of research-based pharmaceuticals focused on oncology and infectious diseases, leveraging protease inhibitor design and nucleotide/nucleoside science to address unmet medical needs. Portfolio includes MIV-818 for liver cancer, remetinostat for early-stage MF-CTCL, and VBX-1000 with positive proof-of-concept results. Also offers quarterly report conference calls and investor presentations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Medivir company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Canopy Biosciences
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Canopy Biosciences
2.2 - Growth funds investing in similar companies to Canopy Biosciences
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Canopy Biosciences
4.2 - Public trading comparable groups for Canopy Biosciences
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →